UMB Bank n.a. Raises Position in Repligen Co. (NASDAQ:RGEN)

UMB Bank n.a. grew its position in shares of Repligen Co. (NASDAQ:RGEN) by 49.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 334 shares of the biotechnology company’s stock after acquiring an additional 110 shares during the period. UMB Bank n.a.’s holdings in Repligen were worth $48,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Champlain Investment Partners LLC increased its stake in shares of Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares in the last quarter. DF Dent & Co. Inc. raised its position in shares of Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after purchasing an additional 139,615 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Repligen by 39.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after purchasing an additional 121,305 shares in the last quarter. Two Sigma Advisers LP increased its stake in Repligen by 421.9% during the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock valued at $18,796,000 after purchasing an additional 102,100 shares in the last quarter. Finally, Fred Alger Management LLC lifted its stake in shares of Repligen by 29.5% in the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock worth $59,313,000 after buying an additional 90,831 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of several analyst reports. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. HC Wainwright dropped their target price on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $184.73.

Repligen Price Performance

Shares of Repligen stock opened at $165.89 on Friday. The company has a market capitalization of $9.29 billion, a price-to-earnings ratio of -448.34, a PEG ratio of 4.51 and a beta of 0.97. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock’s 50-day simple moving average is $150.83 and its 200-day simple moving average is $146.23. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the firm posted $0.23 EPS. The company’s revenue was up 9.7% on a year-over-year basis. As a group, analysts expect that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.